• Busca personas
• Intranet

Cáncer genitourinario Joaquim Bellmunt

Publicaciones 2024 (9)

• Jiménez N, Garcia de Herreros M, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, García-Esteve S, Rodríguez-Carunchio L, Trias I, Font A, Rodríguez-Vida A, Climent MÁ, Cros S, Chirivella-Gonzalez I, Domenech M, Figols M, Carles J, Suárez C, Herrero-Rivera D, González-Billalabeitia E, Cívico C, Sala-González N, Ruiz de Porras V, Ribal MJ, Prat A, Mellado B^*. Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients. Eur Urol Oncol 2024: (en Premsa).
• Pal SK^*, Grivas P, Gupta S, Dizman N, Zengin Z, Valderrama BP, Rodríguez-Vida A, Roghmann F, Sevillano-Fernandez E, Matin SF, Loriot Y, Sridhar SS, Sonpavde G, Fleming MT, Lerner SP, Bellmunt J, Master V, Tripathi A, Davis K, van Veenhuyzen D, Weng R, Daneshmand S. Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial. Eur Urol 2024: (en Premsa).
• Romero-Laorden N, Lorente D, De Velasco G, Lozano R, Herrera B, Puente J, López PP, Medina A, Almagro E, González-Billalabeitia E, Villa-Guzmán JC, González del Alba A, Borrega P, Laínez N, Fernández-Freire A, Hernández A, Rodríguez-Vida A, Chirivella I, Fernández-Parra EM, López-Campos F, Pacheco MI, Morales-Barrera R, Fernández O, Villatoro R, Luque R, Hernando S, Castellano DC, Castro E, Olmos D^*. Prospective Assessment of Bone Metabolism Biomarkers and Survival in Metastatic Castration-resistant Prostate Cancer Patients Treated with Radium-223: The PRORADIUM Study. Eur Urol Oncol 2024; 7(3): 447-455.
• Climent MÁ, Alvarez C, Morales R, Maroto P, Rodríguez-Vida A, Mendez-Vidal MJ, García del Muro X, Puente J, Lainez N, Vazquez S, Castellano D, Gomez-Lang C, Wang J, di Pietro a, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP^*. Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial. Clin Transl Oncol 2024; 26(6): 1532-1538.
• Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, Lorusso P, Wainberg Z, Cervantes A, Rodríguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B^*. Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103). J Clin Pharmacol 2024; 64(5): 544-554.
• Robbrecht D, Grob JJ, Bechter O, Simonelli M, Doger B, Borbath I, Butler MO, Cheng T, Martin-Romano P, Pons-Tostivint E, Di Nicola M, Curigliano G, RYU MH, Rodríguez-Vida A, Schadendorf D, Garralda E, Abbadessa G, Demers B, Amrate A, Wang H, Lee JS, Pomponio R, Wang R^*. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors. CTS-Clin. Transl. Sci. 2024; 17(2): e13736.
• Font A^*, Mellado B^*, Climent MA, Virizuela JA, Oudard S, Puente J, Castellano D, González del Alba A, Pinto A, Morales-Barrera R, Rodríguez-Vida A, Fernandez PL, Teixido C, Jares P, Aldecoa I, Gibson N, Solca F, Mondal S, Lorence RM, Serra J, Real FX^*. Phase II trial of afatinib in patients with advanced urothelial carcinoma with genetic alterations in ERBB1-3 (LUX-Bladder 1). Br J Cancer 2024; 130(3): 434-441.
• Zamora V, Garin O^*, Suárez JF, Gutiérrez C, Guedea F, Cabrera P, Castells M, Herruzo I, Fumadó L, Samper P, Ferrer C, Regis L, Pont A, Ferrer M^*, Multicentric Spanish Group of Clinically Localized Prostate Cancer. Comparative effectiveness of new treatment modalities for localized prostate cancer through patient-reported outcome measures. Clin Transl Radiat Oncol . 2024; 44: 100694 (Acceptat).
• Everaerts W, Walz J, Abascal J, Goffin K, Grootendorst MR, Van't Klooster K, Juanpere N, Valhondo-Rama R, Vidal-Sicart S, Fumadó L^*. A Multicentre Clinical Trial Evaluating a Drop-in Gamma Probe for Minimally Invasive Sentinel Lymph Node Dissection in Prostate Cancer. Eur Urol Focus 2024; 10(1): 32-40.